z-logo
Premium
Serum‐independent Cardiomyogenic Transdifferentiation in Human Endometrium‐derived Mesenchymal Cells
Author(s) -
Ikegami Yukinori,
Miyoshi Shunichiro,
Nishiyama Nobuhiro,
Hida Naoko,
Okamoto Kazuma,
Miyado Kenji,
Segawa Kaoru,
Ogawa Satoshi,
Umezawa Akihiro
Publication year - 2010
Publication title -
artificial organs
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.684
H-Index - 76
eISSN - 1525-1594
pISSN - 0160-564X
DOI - 10.1111/j.1525-1594.2009.00859.x
Subject(s) - transdifferentiation , mesenchymal stem cell , chemistry , microbiology and biotechnology , stem cell , biology
Media with high concentrations of serum are commonly used to induce cardiomyogenic transdifferentiation in mesenchymal stem cells; however, serum contains numerous unknown growth factors and interferes with definition of specific cardiomyogenic transdifferentiation factors secreted from feeder cells. In the present study, we determined whether the transdifferentiation of human mesenchymal cells can be observed in a FBS‐free medium. The efficiency of transdifferentiation was observed in 10% FBS‐containing standard medium (10%FBS) and in FBS‐free medium containing insulin and thyroxin (FBS‐free). In the present study, we used human uterine endometrium‐derived mesenchymal cells (EMC100, EMC214) and menstrual blood‐derived mesenchymal cells (MMCs). After cardiomyogenic transdifferentiation, the efficiency and physiological properties of cardiomyogenesis (fractional shortening of the cell [%FS] and action potential [AP]) were evaluated. The efficiency of transdifferentiation in EMC100 and in MMCs increased 36%* and 163%* (* P  < 0.05), respectively. The %FS in EMCs increased to 103%*. AP‐duration more than 250 ms with a marked plateau was only observed in FBS‐free (3/19), and not in 10% FBS (0/41). The cardiomyogenic transdifferentiation of human mesenchymal cells can be observed in the FBS‐free medium. Phenotypes of generated cardiomyocytes were significantly more physiological in FBS‐free than in 10% FBS.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here